We have two compounds in Phase II clinical development that have been specifically designed with best-in-class properties. Betrixaban, our oral, once-daily, Factor Xa inhibitor anticoagulant and elinogrel, our i.v. and oral antiplatelet agent that is a direct-acting (not a prodrug), reversible P2Y12 ADP receptor antagonist. Both compounds have the potential to meet significant unmet patient needs in the growing multi-billion dollar thrombosis markets.

We also have a robust preclinical pipeline leveraging our in-house research and development expertise. We have a FXa inhibitor antidote in development to address potential bleeding issues from use of a FXa inhibitor, a Syk and JAK inhibitor program focused on compounds to treat rheumatoid arthritis and certain cancers, and an aspirin replacement therapy for aspirin intolerant patients.